迪哲医药：2025年营业收入8.01亿元，同比增长122.60%

Core Viewpoint - Dize Pharmaceutical reported a significant increase in revenue for 2025, with a total of 801 million yuan, representing a year-on-year growth of 122.60% [1] Financial Performance - The company achieved a revenue of 801 million yuan in 2025, which is a 122.60% increase compared to the previous year [1] - The net profit attributable to the parent company was -763 million yuan, an improvement from -846 million yuan in the same period last year [1] Product Development and Market Expansion - Two products, Shuwozhe® (generic name: Shuwotini tablets) and Gaoruizhe® (generic name: Golexini capsules), have been included in the national medical insurance drug list, enhancing patient accessibility [1] - The company is actively promoting its products and expanding market share, which has positively impacted its operations [1]